Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.

British journal of cancer - 1 May 2018

Adler Nikki R, Wolfe Rory, McArthur Grant A, Kelly John W, Haydon Andrew, McLean Catriona A, Mar Victoria J

Abstract excerpt

BACKGROUND: A proportion of patients develop recurrence following a tumour-negative sentinel lymph node biopsy (SLNB). This study aimed to explore whether melanoma patients with BRAF or NRAS mutant tumours have an increased risk of developing disease recurrence following a negative SLNB compared to patients with wild-type tumours. METHODS: Prospective cohort study of melanoma patients at three tertiary referral...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Disease-Free Survival
Share to GTP Phosphohydrolases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Melanoma

Share to Melanoma, Cutaneous Malignant

Share to Membrane Proteins

Share to Neoplasm Recurrence, Local

Share to Proto-Oncogene Proteins B-raf

Share to Skin Neoplasms

Source

Open in PubMed Open full text

Identifiers

PMID: 29755118
DOI: 10.1038/s41416-018-0088-8
PMCID: PMC5959932

Genes

BRAF
NRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tumour mutation status and melanoma recurrence following a negative sentinel lymph node biopsy.PMID 29755118Read ↗

BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.Semantic proximity Read ↗

Tumor mutational burden and somatic mutation status to predict disease recurrence in advanced melanoma.Semantic proximity Read ↗

Metastatic patterns, clinical outcome, and malignant phenotype in malignant cutaneous melanoma.Semantic proximity Read ↗

Serum‐based miRNAs in the prediction and detection of recurrence in melanoma patientsSemantic proximity Read ↗

Markers of circulating tumour cells in the peripheral blood of patients with melanoma correlate with disease recurrence and progression.Semantic proximity Read ↗

Melanoma MicroRNA Signature Predicts Post-Recurrence SurvivalSemantic proximity Read ↗

Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial.Semantic proximity Read ↗

The concepts of rechallenge and retreatment in melanoma: A proposal for consensus definitions.Semantic proximity Read ↗

Two cutaneous malignant melanomas at the same anatomic site: a case report with molecular evaluation.Semantic proximity Read ↗

Malignant melanoma: relationship of the human leukocyte antigen class II gene DQB1*0301 to disease recurrence in American Joint Committee on Cancer Stage I or II.Semantic proximity Read ↗

Mutated BRAF Emerges as a Major Effector of Recurrence in a Murine Melanoma Model After Treatment With Immunomodulatory Agents.Semantic proximity Read ↗

Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.